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Address patient concerns about TB 
and treatment side effects
Patients’ understanding of tuberculosis—the 
disease, the treatment, and the outcome—poses
an important challenge in the care of an 
asymptomatic PPD-positive patient. These patients
may ask, “Will I get sick? Do I have to take the
medicine? Are there side effects? And would you
take the medicine?” We need to be prepared to
answer these questions.
Most patients with a positive PPD will not get
active tuberculosis, but when they do it can be
serious and it can spread easily. The medication
significantly decreases the risk of developing active
tuberculosis. The medication side effects are
uncommon but can be severe. These side effects
are reversible if the medication is stopped 
promptly. Under the supervision of my physician, 
I would take the medicine.
Richard Guthmann, MD
University of Illinois at Chicago/Advocate Illinois
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Clinical evaluation and chest x-ray are 
recommended for asymptomatic patients with a
positive purified protein derivative (PPD) test
result, to exclude the slight possibility of active
tuberculosis (TB). Patients with radiographic 
evidence of old (healed) TB infection should also
undergo sputum testing (strength of recommenda-
tion [SOR]: C, expert opinion). 
Treatment with isoniazid (INH) monotherapy (300
mg/d) reduces progression of latent tuberculosis 
to active disease (SOR: A, large randomized 
controlled trials [RCT]), with 9 months as the 
optimal treatment length (SOR: B, derivation from
RCTs). A 3-month course of combined rifampin
(600 mg/d) and INH (300 mg/d) is equivalent in 
efficacy to INH monotherapy and is associated with
similar rates of toxicity (SOR: A, meta-analysis 
of RCTs), but this regimen is not included in
Centers for Disease Control and Prevention 
recommendations. 
C L I N I C A L C O M M E N T A R Y
n Evidence summary
Clinical evaluation with medical history
and physical exam, chest radiography,
and selected sputum sampling to exclude
active tuberculosis are part of the recom-
mended algorithm for all patients who
develop a positive PPD (FIGURE).1–3 These
recommendations are derived from
expert opinion, and their usefulness has
not been evaluated in any population-
based study of asymptomatic PPD-posi-
tive patients. 
A comprehensive review of RCTs from
the 1950s and 1960s demonstrated that
INH treatment of patients with latent
tuberculosis infection is effective in
decreasing the progression to active tuber-
culosis.4 A series of double-blinded RCTs
performed by the US Public Health Service
included 25,923 patients with latent tuber-
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Clinical evaluation
and chest x-ray
are recommended
for those with 
a positive PPD,
even though the
chances of active
TB are slight
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culosis who were randomized to receive
either daily INH or placebo for 1 year with
6- to 10-year follow-up. Groups studied
included household contacts of patients
with active tuberculosis (rate of progres-
sion to active disease in placebo group
[baseline rate]=27/1000, relative risk with
INH [RR]=0.4, number needed to treat
[NNT]=63), patients in mental institutions
(baseline rate=12/1000, RR=0.3, NNT=121),
and patients with x-ray findings of healed
tuberculosis (baseline rate=69/1000,
RR=0.4, NNT=23). 
The optimal length of treatment for
PPD-positive patients without active dis-
ease was evaluated through 1 double-
blinded RCT enrolling 28,000 patients
with 5-year follow-up after 12, 24, or 52
weeks of INH or placebo. Active TB devel-
oped in 0.35% (24/6919) after 52 weeks
of INH compared with 0.49% (34/6965)
after 24 weeks (RR=1.4, NNT=708).5
Incidence in the placebo group was 1.4%.
Subgroup analysis determined that maxi-
mum efficacy with fewest side effects was
achieved at 9 months.6 Nine months of
INH is also recommended for HIV-positive
patients, based on extrapolations from
these and other studies.3
INH monotherapy was compared with
combination INH and rifampin in a 2005
meta-analysis of 5 RCTs of variable quali-
ty involving 1926 patients.7 This meta-
analysis found equivalency in risk of active
TB and mortality between INH monother-
apy for 6 to 12 months and the combina-
tion of rifampin and INH for 3 months
(pooled risk difference=0%; 95% confi-
dence interval [CI], –1% to 2%). This
study also showed similar rates of adverse
events in both groups (pooled risk differ-
ence = –1%; 95% CI, –7% to 5%). Short-
course combination rifampin and pyrazi-
namide is no longer recommended after an
open-label RCT with 589 patients demon-
strated severe hepatoxicity in 7.7%
(16/207) on a 2-month course of pyrazi-
namide and rifampin, compared with 1%
(2/204) on 6 months of INH (RR=7.9,
number needed to harm=15).8 Rifampin
monotherapy has only been studied in
patients with silicosis in a RCT enrolling
652 participants with latent tuberculosis. A
12-week course of rifampin (600 mg daily)
was as effective as 6 months of INH in pre-
venting development of active TB over the
next 5 years.9
Recommendations from others
Centers for Disease Control and
Prevention, American Thoracic Society,
and Infectious Disease Society of America
guidelines recommend targeted screening
of high-risk persons followed by further
clinical evaluation of all those with a reac-
tive PPD (FIGURE).2,10 The recommended
treatment regimen for latent TB is daily
INH for 9 months. Less preferable regi-
mens are daily INH for 6 months, or daily
rifampin for 4 months in patients who can-
not tolerate INH. A 2-month course of
rifampin and pyrazinamide is no longer
recommended. The recent meta-analysis
supporting a 3-month regimen of combina-
tion INH and rifampin has not been incor-
porated into expert guidelines.7
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